Targeted beta therapy of prostate cancer with 177Lu-labelled Miltuximab® antibody against glypican-1 (GPC-1)

Abstract Purpose Chimeric antibody Miltuximab®, a human IgG1 engineered from the parent antibody MIL-38, is in clinical development for solid tumour therapy. Miltuximab® targets glypican-1 (GPC-1), a cell surface protein involved in tumour growth, which is overexpressed in solid tumours, including p...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Mei-Chun Yeh, Brian W. C. Tse, Nicholas L. Fletcher, Zachary H. Houston, Maria Lund, Marianna Volpert, Chelsea Stewart, Kamil A. Sokolowski, Varinder Jeet, Kristofer J. Thurecht, Douglas H. Campbell, Bradley J. Walsh, Colleen C. Nelson, Pamela J. Russell
Formato:	Artigo
Idioma:	Inglês
Publicado em:	SpringerOpen 2020-05-01
coleção:	EJNMMI Research
Assuntos:	Prostate cancer Radionuclide therapy Miltuximab® Glypican-1 MIL-38
Acesso em linha:	http://link.springer.com/article/10.1186/s13550-020-00637-x
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!